Literature DB >> 25115669

Pulmonary embolism in burns, is there an evidence based prophylactic recommendation? Case report and review of literature.

Raul Sebastian1, Omar Ghanem2, Frank DiRoma1, Stephen M Milner1, Leigh A Price3.   

Abstract

Burn patients exhibit an acquired hypercoagulable state with increased risk of venous thromboembolism. Currently, no randomized control study assessing the efficacy of chemical venous thromboembolism (VTE) prophylaxis in burn patients has been performed. We present a case of a morbidly (body mass index>54kg/m(2)) obese patient with 18% total body surface area (TBSA) burn who developed a VTE and a non-fatal submassive pulmonary embolus (PE). We will be reviewing the current consensus of venous thrombosis prophylaxis in burn patients and briefly discuss the treatment of PE in this population.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Acquired hypercoagulopathy; Blood clot; Burn wounds; Deep venous thrombosis; Pulmonary embolism; Venous thromboembolism

Mesh:

Substances:

Year:  2014        PMID: 25115669     DOI: 10.1016/j.burns.2014.06.018

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  3 in total

1.  Increased risk of ischemic stroke in patients with burn injury: a nationwide cohort study in Taiwan.

Authors:  Tzu-Yao Hung; Yi-Kung Lee; Ming-Yuan Huang; Chen-Yang Hsu; Yung-Cheng Su
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-04-06       Impact factor: 2.953

2.  The conundrum of deep vein thrombosis prophylaxis in burns in India and review of literature.

Authors:  S S Shirol; Srinivas Kodaganur; M Raghavendra Rao; Vinaykumar Tiwari
Journal:  Indian J Plast Surg       Date:  2017 Sep-Dec

3.  Risk factors for thromboembolism in burn patients admitted to the burn unit at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.

Authors:  Thamer A Althunayan; Saad M AlQarni; Waleed A Mohsenh; Ahmed M Alkhalifah; Abdullmajeed N Alsadi; Omar S Alrushid; Mohammad M Al-Qattan
Journal:  Saudi Med J       Date:  2019-10       Impact factor: 1.484

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.